Clinical significance of the long noncoding RNA RP11-19P22.6-001 in gastric cancer.
Long non-coding RNAs (lncRNAs) play roles in carcinogenesis; however, the significance of most lncRNAs in gastric cancer is unclear. To explore the diagnostic value of the long noncoding RNA RP11-19P22.6-001 in gastric cancer. RP11-19P22.6-001 levels in gastric cancer tissues and paired non-tumor tissues were analyzed by quantitative reverse transcription-polymerase chain reaction. Since RP11-19P22.6-001 acts in cis to regulate nitric oxide synthase 2 (NOS2), we also analyzed NOS2 expression and its correlation with gastric cancer. Finally, to analyze the potential diagnostic values of RP11-19P22.6-001, a receiver operating characteristic (ROC) curve was constructed. RP11-19P22.6-001 expression was significantly downregulated in 70.91% (78/110) of gastric cancer tissues compared to that of adjacent normal tissues. However, NOS2 was upregulated in 75.45% (83/110) of gastric cancer tissues. RP11-19P22.6-001 expression levels were associated with invasion, lymph node metastasis, and TNM stage. The areas under the ROC curves (AUC) were 0.662 and 0.671 for RP11-19P22.6-001 and NOS2, respectively. More importantly, the combined use of these parameters increased the AUC to 0.704. RP11-19P22.6-001 and NOS2 may be new biomarkers for the diagnosis and prognosis of gastric cancer. The combined use of lncRNAs and their target genes may be a promising method to increase the diagnostic value of lncRNAs in cancer.